NasdaqGS - Delayed Quote USD

Roivant Sciences Ltd. (ROIV)

11.18 +0.05 (+0.45%)
At close: May 13 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Matthew Gline CEO & Director 1.77M -- 1984
Dr. Eric Venker M.D., Pharm.D. President & COO 1.28M -- 1987
Dr. Mayukh Sukhatme M.D. President, Chief Investment Officer & Director 1.72M -- 1976
Mr. Richard Pulik Chief Financial Officer -- -- 1979
Ms. Rakhi Kumar Chief Accounting Officer -- -- 1980
Dr. Huafeng Xu Ph.D. Chief Technology Officer -- -- --
Mr. Jo Chen General Counsel -- -- --
Ms. Kelly Graff Head of People -- -- --
Ms. Marianne L. Romeo Head of Global Transactions & Risk Management -- -- 1968
Mr. Alex Gasner Executive Vice President of Roivant Health -- -- --

Roivant Sciences Ltd.

50 Broadway
7th Floor
London, SW1H 0DB
United Kingdom
44 20 7400 3347 https://roivant.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
904

Description

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Corporate Governance

Roivant Sciences Ltd.’s ISS Governance QualityScore as of May 1, 2024 is 9. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 3; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Jun 26, 2024 - Jul 01, 2024
Roivant Sciences Ltd. Earnings Call

Related Tickers

BBIO BridgeBio Pharma, Inc.
28.50
-2.06%
 
IMVT Immunovant, Inc.
29.88
+1.67%
 
CYTK Cytokinetics, Incorporated
57.89
-6.78%
 
ABUS Arbutus Biopharma Corporation
2.8900
+0.35%
 
TIL Instil Bio, Inc.
11.80
+1.90%
 
LEGN Legend Biotech Corporation
42.97
-0.62%
 
RPRX Royalty Pharma plc
28.38
+1.03%
 
SPRO Spero Therapeutics, Inc.
1.6500
+0.61%
 
ASND Ascendis Pharma A/S
132.02
-1.08%
 
KRYS Krystal Biotech, Inc.
154.82
+0.04%